Illumina Drops Plans for Lower-Throughput NovaSeq System as It Eyes Clinical Market Growth – GenomeWeb

Illumina Drops Plans for Lower-Throughput NovaSeq System as It Eyes Clinical Market Growth
GenomeWeb
The payor will also cover trio exome sequencing. It noted, however, that it considers whole-genome sequencing to be unproven and "not medically necessary for any disorder." The new policy takes effect starting in November, and deSouza said that now

and more »

Source: Genome Sequencing